Janssen Alzheimer Immunotherapy is a Pharmaceutical Research and Development subsidiary company of Johnson & Johnson. Its current focus is on Alzheimer Disease and recently (2012) completed a series of Phase 3 studies on its primary drug bapineuzumab.

Publications show all

Janssen Alzheimer Immunotherapy has published 29 articles.

Patents show all

145Issued120Applications

Clinical Trials show all

13Phase 23Phase 32Phase 11N/A